Wenjun Zhou

发表

Systematic identification of genomic markers of drug sensitivity in cancer cells

S. Ramaswamy, M. Stratton, P. Futreal, 2012, Nature.

Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation

Wenjun Zhou, Yi Zhang, Zheng Peng, 2018, Medical science monitor : international medical journal of experimental and clinical research.

Expression and significance of TIMP-3, PACAP and VIP in vaginal wall tissues of patients with stress urinary incontinence

Wenjun Zhou, Yi Shi, Xiaohua Jin, 2016, Experimental and therapeutic medicine.

A structure-guided approach to creating covalent FGFR inhibitors.

Scott B Ficarro, Nathanael S Gray, Matthew Meyerson, 2010, Chemistry & biology.

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

P. Jänne, N. Gray, Wenjun Zhou, 2012, Bioorganic & medicinal chemistry letters.

Activating mutations in ALK provide a therapeutic target in neuroblastoma

D. Gary Gilliland, Stefan Fröhling, Wendy B. London, 2008, Nature.

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

John R. Engen, Kwok-Kin Wong, Liang Chen, 2009, Nature.

Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases

N. Gray, Wenjun Zhou, Xianming Deng, 2013, The Biochemical journal.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

A. Iafrate, T. Shioda, U. McDermott, 2008, Cancer research.

Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs.

T. Lagerweij, T. Wurdinger, N. Gray, 2013, Journal of the National Cancer Institute.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

M. Meyerson, I. Petersen, R. Onofrio, 2011, Cancer discovery.

in squamous cell lung cancer

M. Meyerson, I. Petersen, R. Onofrio, 2011 .

Mutations in the DDR 2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer

M. Meyerson, I. Petersen, R. Onofrio, 2011 .

The STAT3/NFIL3 signaling axis‐mediated chemotherapy resistance is reversed by Raddeanin A via inducing apoptosis in choriocarcinoma cells

Wenjun Zhou, Yi Zhang, Zheng Peng, 2018, Journal of cellular physiology.

TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Angela G. Fleischman, L. Staudt, D. Neuberg, 2013, Cancer discovery.

Expression profiles of tRNA-derived fragments and their potential roles in ovarian endometriosis.

Wenjun Zhou, Yi Zhang, Licong Shen, 2019, Epigenomics.

1 TYK 2-STAT 1-BCL 2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia

Angela G. Fleischman, L. Staudt, D. Neuberg, 2013 .

TYK 2 – STAT 1 – BCL 2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia

Angela G. Fleischman, L. Staudt, D. Neuberg, 2013 .

The miR-25-3p/Sp1 pathway is dysregulated in ovarian endometriosis

Wenjun Zhou, Yi Zhang, Yang Liu, 2020, The Journal of international medical research.

ILK-induced epithelial-mesenchymal transition promotes the invasive phenotype in adenomyosis.

Wenjun Zhou, Yi Zhang, Zheng Peng, 2018, Biochemical and biophysical research communications.

Chemical Interrogation of the Malaria Kinome

N. Gray, Wenjun Zhou, M. Mota, 2014, Chembiochem : a European journal of chemical biology.

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.

S. Knapp, N. Gray, Wenjun Zhou, 2012, Chemistry & biology.

Discovery of selective irreversible inhibitors for EGFR-T790M.

Nathanael S Gray, P. Jänne, N. Gray, 2011, Bioorganic & medicinal chemistry letters.

Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

N. Gray, Wenjun Zhou, H. Choi, 2010, Molecular Cancer Therapeutics.

Molecular Cancer apeutics apeutic Discovery overy and Characterization of Novel Mutant Ther 3 Kinase Inhibitors

Ellen, N. Gray, Wenjun Zhou, 2010 .

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

James D. Griffin, Andrew L. Kung, Taebo Sim, 2010, Blood.

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Rachel G Liao, S. Gaudet, P. Jänne, 2014, Proceedings of the National Academy of Sciences.

Expression of miR-451a in Prostate Cancer and Its Effect on Prognosis

Wenjun Zhou, Yi Shi, Xiaohua Jin, 2021, Iranian journal of public health.

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.

N. Gray, Wenjun Zhou, Tinghu Zhang, 2018, Journal of medicinal chemistry.

Abstract 2809: Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia

L. Staudt, A. Look, N. Gray, 2011 .

Circular RNA expression in ovarian endometriosis.

Wenjun Zhou, Yi Zhang, Zheng Peng, 2018, Epigenomics.

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.

N. Gray, Wenjun Zhou, Tinghu Zhang, 2018, Journal of medicinal chemistry.

Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases

N. Gray, Wenjun Zhou, Xianming Deng, 2013, The Biochemical journal.